Abstract Esophageal squamous cell carcinoma is one of the most common malignant tumors in China. Neoadjuvant chemoradiotherapy combined with surgery significantly improved the survival rate of locally advanced operable esophageal squamous cell carcinoma, but approximately half of the patients had poor or no efficacy. To accurately predict the efficacy of neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma and select the dominant population of neoadjuvant chemoradiotherapy, many studies on biomarkers have emerged, which have promoted the progress of neoadjuvant therapy for esophageal squamous cell carcinoma to some extent. In this article, the studies on biomarkers predicting the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma were reviewed.
Fund:The Technology Open and Cooperation Program of Henan (182106000062); Science and Technology Project of Henan Province (222102310253)
Corresponding Authors:
Ge Hong, Email: gehong666@126.com
Cite this article:
Zheng Xiaoli,Jiao Ruidi,Yang Yang et al. Research progress on biomarkers related to the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(10): 949-954.
Zheng Xiaoli,Jiao Ruidi,Yang Yang et al. Research progress on biomarkers related to the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(10): 949-954.
[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660. [2] Wu YH, Lin MQ, Wang ZP, et al.Clinical significance of risk stratification of esophageal squamous cell carcinoma after neoadjuvant chemoradiation and surgery[J]. Transl Oncol, 2021,14(5):101037.DOI: 10.1016/j. tranon. 2021.101037. [3] Shapiro J, van Lanschot J, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. [4] Yang H, Liu H, Chen Y, et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2796-2803. DOI: 10.1200/JCO.2018.79.1483. [5] van der Wille BJ, Noordman BJ, Neijenhuis L, et al. Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study[J]. Ann Surg, 2021,274(6):1009-1016. DOI: 10.1097/SLA.000000000000 3636. [6] Eyck BM, Onstenk BD, Noordman BJ, et al.Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis[J]. Ann Surg, 2020,271(2):245-256. DOI: 10.1097/SLA. 0000000000003397. [7] 韩炜明, 肖泽芬. 多模态影像组学检查在食管癌放化疗疗效评估的临床价值与研究进展[J].中华放射肿瘤学杂志,2020,29(7):583-588. DOI: 10.3760/cma.j.cn113030-20190210- 00046. Han WM, Xiao ZF.Clinical value and research progress on multimodal radiological and radiomic examinations in evaluating the clinical efficacy of chemoradiotherapy for esophageal cancer[J].Chin J Radiat Oncol,2020,29(7):583-588. DOI: 10.3760/cma.j.cn113030-20190210-00046. [8] Noda M, Okumura H, Uchikado Y, et al.Correlation between biomarker candidate proteins with the effect of neoadjuvant chemoradiation therapy on esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2018,25(2):449-455. DOI: 10.1245/s10434-017-6271-y. [9] Gombodorj N, Yokobori T, Tanaka N, et al.Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: a retrospective study[J]. J Surg Oncol, 2018,118(1):101-108. DOI: 10.1002/jso.25127. [10] Zhou S, Zhao L, Liang Z, et al. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy[J]. Cancers (Basel), 2019,11(2)DOI: 10.3390/cancers11020169. [11] Huang WT, Lu HI, Wang YM, et al. Positive programmed cell death-ligand 1 expression predicts poor treatment outcomes in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiotherapy[J]. J Clin Med, 2019,8(11)DOI: 10.3390/jcm8111864. [12] Hsu FM, Cheng JC, Chang YL, et al.Circulating mRNA profiling in esophageal squamous cell carcinoma identifies FAM84B as a biomarker in predicting pathological response to neoadjuvant chemoradiation[J]. Sci Rep, 2015,5:10291. DOI: 10.1038/srep10291. [13] Wen J, Yang H, Liu MZ, et al.Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo- chemoradiotherapy[J]. Ann Oncol, 2014,25(9):1769-1774. DOI: 10.1093/annonc/mdu201. [14] Zhang C, Zhang G, Sun N, et al.An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma[J]. Signal Transduct Target Ther, 2020,5(1):182. DOI: 10.1038/s41392-020-00221-8. [15] Wen J, Luo K, Liu H, et al.MiRNA expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy[J]. Ann Surg, 2016,263(5):942-948. DOI: 10.1097/SLA.0000000000001489. [16] Zhang C, Zhang Z, Zhang G, et al.A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy[J]. Clin Transl Med, 2020,10(4):e156. DOI: 10.1002/ctm2.156. [17] McLaren PJ, Bronson NW, Hart KD, et al. Neutrophil- to-lymphocyte and platelet-to-lymphocyte ratios can predict treatment response to neoadjuvant therapy in esophageal cancer[J]. J Gastrointest Surg, 2017,21(4):607-613. DOI: 10.1007/s11605-016-3351-4. [18] 冯卓, 罗辉, 孙亚楠, 等. 纤维蛋白原联合中性粒细胞与淋巴细胞比值在新辅助治疗食管鳞癌患者预后中的临床意义[J].中华放射肿瘤学杂志,2019,28(3):188-192. DOI: 10.3760/cma.j.issn.1004-4221.2019.03.006. Feng Z, Luo H, Sun YN, et al.Prognostic significance of fibrinogen concentration combined with neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma patients receiving neoadjuvant therapy[J].Chin J Radiat Oncol,2019,28(3):188-192. DOI: 10.3760/cma.j.issn.1004-4221.2019.03.006. [19] Qian D, Wang Y, Zhao G, et al.Tumor remission and tumor-infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019,105(2):319-328. DOI: 10.1016/j.ijrobp.2019. 06.079. [20] Bouaoun L, Sonkin D, Ardin M, et al.TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data[J]. Hum Mutat, 2016,37(9):865-876. DOI: 10.1002/humu.23035. [21] Alvarado-Ortiz E, de la Cruz-López KG, Becerril-Rico J, et al. Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches[J]. Front Cell Dev Biol, 2020,8:607670. DOI: 10.3389/fcell.2020.607670. [22] Aubrey BJ, Kelly GL, Janic A, et al.How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?[J]. Cell Death Differ, 2018,25(1):104-113. DOI: 10.1038/cdd.2017.169. [23] Wagata T, Shibagaki I, Imamura M, et al.Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas[J]. Cancer Res, 1993,53(4):846-850. [24] Kim MK, Cho KJ, Kwon GY, et al.ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer[J]. Eur J Cancer, 2008,44(1):54-60. DOI: 10.1016/j.ejca.2007.09.006. [25] Yumimoto K, Nakayama KI. Recent insight into the role of fbxw7 as a tumor suppressor[J]. Semin Cancer Biol, 2020,67(Pt 2):1‐15.DOI: 10.1016/j. semcancer. 2020.02.017. [26] Zhang Q, Mady A, Ma Y, et al.The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response[J]. Nucleic Acids Res, 2019,47(8):4039-4053. DOI: 10.1093/nar/gkz058. [27] Cui D, Xiong X, Shu J, et al. FBXW7 confers radiation survival by targeting p53 for degradation[J]. Cell Rep, 2020,30(2):497-509.e4. DOI: 10.1016/j.celrep.2019.12.032. [28] Benjamin JM, Nelson WJ. Bench to bedside and back again: Molecular mechanisms of alpha‐catenin function and roles in tumorigenesis[J]. Semin Cancer Biol, 2008,18(1):53‐64.DOI: 10.1016/j. semcancer. 2007.08.003. [29] Ming XY, Zhang X, Cao TT, et al.RHCG suppresses tumorigenicity and metastasis in esophageal squamous cell carcinoma via inhibiting NF-κB signaling and MMP1 expression[J]. Theranostics, 2018,8(1):185-198. DOI: 10.7150/thno.21383. [30] Liu M, Hu Y, Zhang MF, et al.MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma[J]. Cancer Lett, 2016,377(1):97-104. DOI: 10.1016/j.canlet.2016. 04.034. [31] Lin YH, Zhen YY, Chien KY, et al.LIMCH1 regulates nonmuscle myosin-II activity and suppresses cell migration[J]. Mol Biol Cell, 2017,28(8):1054-1065. DOI: 10.1091/mbc.E15-04-0218. [32] Wang K, Xing ZH, Jiang QW, et al.Targeting uPAR by CRISPR/Cas9 system attenuates cancer malignancy and multidrug resistance[J]. Front Oncol, 2019,9:80. DOI: 10.3389/fonc.2019.00080. [33] Smith HW, Marshall CJ.Regulation of cell signalling by uPAR[J]. Nat Rev Mol Cell Biol, 2010,11(1):23-36. DOI: 10.1038/nrm2821. [34] Saidak Z, Soudet S, Lottin M, et al.A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment[J]. Cancer Immunol Immunother, 2021,70(4):923-933. DOI: 10.1007/s00262-020-02739-w. [35] Di Leva G, Garofalo M, Croce CM.MicroRNAs in cancer[J]. Annu Rev Pathol, 2014,9:287-314. DOI: 10.1146/annurev-pathol-012513-104715. [36] Lin C, Yang L.Long Noncoding RNA in cancer: wiring signaling circuitry[J]. Trends Cell Biol, 2018,28(4):287-301. DOI: 10.1016/j.tcb.2017.11.008. [37] Siravegna G, Mussolin B, Venesio T, et al.How liquid biopsies can change clinical practice in oncology[J]. Ann Oncol, 2019,30(10):1580-1590. DOI: 10.1093/annonc/mdz227. [38] Iwaya T, Endo F, Takahashi F, et al. Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital polymerase chain reaction[J]. Gastroenterology, 2021,160(1):463-465.e4. DOI: 10.1053/j.gastro.2020.09.035. [39] Cristiano S, Leal A, Phallen J, et al.Genome-wide cell-free DNA fragmentation in patients with cancer[J]. Nature, 2019,570(7761):385-389. DOI: 10.1038/s41586-019-1272-6. [40] Kim EJ, Im HS, Lee J, et al.Genome‐wide and size‐based cell‐free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy[J]. Curr Probl Cancer, 2020:100685.DOI: 10.1016/j. currproblcancer. 2020.100685. [41] Mantovani A, Allavena P, Sica A, et al.Cancer-related inflammation[J]. Nature, 2008,454(7203):436-444. DOI: 10.1038/nature07205. [42] Wouters M, Nelson BH.Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer[J]. Clin Cancer Res, 2018,24(24):6125-6135. DOI: 10.1158/1078-0432.CCR-18-1481.
2022, Vol. 31 
